Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966

Integrin β1 receptor, expressed on the surface of tumor cells and macrophages in the tumor microenvironment (TME), has been implicated in both tumor progression as well as resistance to multiple modalities of therapy. OS2966 is the first clinical-ready humanized monoclonal antibody to block integrin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Lee, Tae Jin, Nair, Mitra, Banasavadi-Siddegowda, Yeshavanth, Liu, Joseph, Nallanagulagari, Tejaswini, Jaime-Ramirez, Alena Cristina, Guo, Jeffrey Yunhua, Quadri, Haroon, Zhang, Jianying, Bockhorst, Kurt H, Aghi, Manish K, Carbonell, W. Shawn, Kaur, Balveen, Yoo, Ji Young
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6548661/
https://ncbi.nlm.nih.gov/pubmed/30926634
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0953
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados